INTRODUCTION
Therapeutic options for patients with cancer, such as melanoma, prostate cancer, and renal cell carcinoma, have increased during the past decade because of improved understanding of tumor biology and availability of targeted agents. Vascular endothelial growth factor (VEGF) and related signaling pathways are considered critically important in the pathogenesis, growth, and development of cancer. Inhibiting the VEGF signaling pathway has been investigated as a therapeutic strategy for cancer, either by blockade of VEGF ligand binding or inhibition of the VEGF receptor (VEGFR) [1] .
Vascular Endothelial Growth Factor
A prevailing hypothesis is that when a tumor outgrows its blood supply, the resulting hypoxia switches on hypoxia inducible factor (HIF) a signaling that stimulates the production of several pro-angiogenic factors [1, 2] . An important pro-angiogenic pathway is that mediated by the VEGF family of ligands, which includes six growth factors [VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor (PlGF)] and three VEGF receptors [2] [3] [4] . The VEGFRs are transmembrane tyrosine kinases present mainly in endothelial cells. When circulating VEGFs bind to VEGFRs, signal transduction pathways are activated that may promote endothelial cell proliferation, differentiation, migration, and angiogenesis [3] . The VEGF/ VEGFR signaling pathway is involved in normal developmental and wound healing processes such as embryologic development, skeletal growth, and wound healing [4] .
In addition, it has been shown that tumor angiogenesis is usually 'dysfunctional', with profound alterations, in terms of shape, size, and permeability, as compared to normal angiogenesis [5] . Anti-angiogenic treatments may lead to, not only inhibition of angiogenesis, but also normalization of such abnormal vasculature, allowing, for example, better extravasation of anticancer drugs in tissues. Such a phenomenon appears to be critical in colorectal cancer (CRC), where indeed anti-angiogenic treatments, such as bevacizumab, are commonly administered in an adjunction to cytotoxic chemotherapy [5] .
Furthermore, VEGF expression in CRC may be associated with metastasis, recurrence, and poor prognosis [6] [7] [8] . Therefore, inhibitors of We also reviewed reference lists and discussed search results with experts. Due to its novel nature, abstracts or presentations of any national or international conference on aflibercept were assessed for inclusion. VEGF with high affinity (Kd % 1 pmol/L) and also binds to PlFGs [13, 14] . Some tumors may become resistant to anti-VEGF therapies because of an increase in the levels of PlGF [13] ; therefore, it is feasible that the binding of aflibercept to PlGF could be of interest because by binding or ''trapping'' both VEGF and PlGF aflibercept could possibly overcome the development of resistance to other drugs such as bevacizumab [14] . In preclinical studies, aflibercept prevented the growth of micrometastases, caused regression and renormalization of vasculature in existing tumors, and inhibited new vascular growth [15, 16] . It is noteworthy that two recent phase 3 trials evaluating the addition of bevacizumab to chemotherapy after first progression in patients with mCRC (Table 4) 
VEGF-BINDING AGENTS

VITAL Trial
The VITAL trial was the second large randomized phase 3 trial to evaluate the efficacy and safety of aflibercept [12] . This was a double-blind, placebo-controlled study of aflibercept as second-line treatment for patients (n = 913) with NSCLC who had progressed after first-line platinum-based therapy ( 
VANILLA and VENICE Trials
The remaining two phase 3 clinical trials of aflibercept were conducted in a first-line setting and in combination with chemotherapy. The VANILLA trial enrolled patients with metastatic pancreatic adenocarcinoma, while the VENICE trial assessed patients with metastatic castration-resistant prostate cancer [46, 47] .
The VANILLA trial was terminated early because of an estimation of decreased survival in patients who received aflibercept vs. control patients (Table 3 ) [46] . The VENICE trial sought to discover an added benefit for the use of aflibercept in patients with metastatic androgen-independent prostate cancer [47] .
The primary endpoint of the study was OS. A total of 1,224 patients were enrolled. Patients were randomized into 1:1 ratio to receive docetaxel/prednisone plus aflibercept or docetaxel/prednisone plus placebo. There was no statistically significant difference in OS between both groups (median OS 22.1 vs.
21.2 months, p = 0.38; respectively); nor in PFS (6.9 vs. 6.2 months, respectively; p = 0.31).
However, patients in the aflibercept arm experienced a higher incidence of grade 3/4 AEs (76.9% vs. 48.5%) which led to discontinuation rates of 43.9% for aflibercept vs. 20.9% in the placebo arm.
Aflibercept: Adverse Events
Adverse reactions to aflibercept were common in phase 1 and 2 trials (Tables 1, 2 ). In the phase 3 VELOUR trial, the tolerability profile for aflibercept plus FOLFIRI was consistent with that reported previously for aflibercept, FOLFIRI, and other anti-VEGF therapies. Aflibercept was associated with hypertension (19.1%), proteinuria (7.9%), and other common chemotherapy-related AEs such as diarrhea, hand-foot syndrome, and neutropenia [45] . In the phase 3 VITAL trial, patients who received aflibercept experienced a higher frequency of grade 3/4 AEs including neutropenia (aflibercept 28.0%, control 21.1%); fatigue (aflibercept 11.1%, control 4.2%); stomatitis (aflibercept 8.8%, control 0.7%) and hypertension (aflibercept 7.3%, control 0.9%) [12] . In the VELOUR trial, the incidence of treatment-related AEs was similar among patients who received aflibercept with prior bevacizumab exposure (AEs, 100% of patients) or no prior bevacizumab exposure (AEs, 98.9% of patients). In the aflibercept component of the study, the frequency of grade 3/4 AEs was similar between patients who had received prior bevacizumab (82.5%) and patients who had no prior bevacizumab experience (83.9%) [45] . In both groups, 25% of aflibercept-treated patients discontinued treatment because of AEs.
The most frequent AEs common to aflibercept and bevacizumab were grade 3/4 neutropenia, diarrhea, asthenia, infections, and stomatitis; however, bevacizumab had a more favorable safety profile with less proteinuria and almost no gastrointestinal or constitutional toxicity. The authors of a meta-analysis of three double-blind, placebo-controlled, phase 3 trials evaluating AEs associated with aflibercept concluded that the most common AEs associated with intravenous aflibercept were hypertension, venous and arterial thromboembolic events, hemorrhage, and proteinuria (Table 5 ) [50] .
BIOMARKERS
Despite extensive efforts, researchers have yet to identify a reliable and reproducible biomarker that allows selection and identification of patients who are most likely to benefit from aflibercept therapy. Circulating biomarkers are currently under evaluation as potential tools to monitor treatment response to anti-VEGF drugs. For some cancers, response to treatment with aflibercept may be monitored by measuring levels of cytokines, growth factors, and myeloid biomarkers. In patients with glioblastoma, treatment with aflibercept was associated with decreased levels of VEGF and PlGF [51] .
Lower levels of growth-regulated oncogene a, hepatocyte growth factor, and stem cell growth factor b, and higher levels of free VEGF, were also associated with a PR in this patient group. Elevated baseline levels of CTACK/CCL27, MCP3/CCL7, MIF, and IP-10/ CXCL10, and a decrease in VEGFR1-positive monocytes from baseline to 24-h postaflibercept administration, have also been associated with improved response in glioblastoma patients [52] . Although, as shown in this review, aflibercept has demonstrated overall survival benefits when combined to FOLFIRI for the treatment of patients with mCRC that is resistant to or has progressed following an oxaliplatin-containing regimen, due to the lack of head to head trials, its place in the treatment paradigm of mCRC, with the availability of similar agents such as bevacizumab, is still not well defined.
Similarly, the best way to combine and sequence all of these drugs to optimize treatment has not yet been established. In some cases, predictive biomarkers can influence the choice of treatment. For instance, patients who harbor a K-ras mutation may benefit from strategies targeting the EGFR [53] 
